- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02387086
Gefitinib Combined With Thalidomide to Treat NSCLC
A Phase III, Multi Center, Randomized, Placebo Controlled Study to Evaluate the Efficacy of the Combination Gefitinib With Thalidomide in Patients With Locally Advanced and Metastatic Non-Small-Cell-Lung-Cancer With EGFR Mutation
연구 개요
상세 설명
Primary Objective:
To determine the 1 year progression-free survival(PFS) rate of the combination of thalidomide with gefitinib in patients who harbors EGFR mutations.
Secondary Objectives:
- To evaluate the objective response rate and 2 years overall survival of this combination therapy;
- To evaluate the safety and tolerability of this combination therapy;
- To acquire preliminary data regarding the effects of thalidomide on interleukin-2 level in serum.
Treatment will be administered on an outpatient basis. Thalidomide starting at a dose of 50mg QD at night. After one week, increase the dose to 100mg QD at night.
Aspirin will be administered at 100mg QD continuously. Gefitinib will be administered at 250mg QD continuously. Maintenance Therapy patients responding to this therapy will be maintained with gefitinib、thalidomide and aspirin.
Duration of Therapy
In the absence of treatment delays due to adverse events, treatment may continue until one of the following criteria applies:
- Disease progression,
- Intercurrent illness that prevents further administration of treatment,
- Unacceptable adverse events(s),
- Patient decides to withdraw from the study, or
- General or specific changes in the patient's condition render the patient unacceptable for further treatment in the judgment of the investigator.
연구 유형
등록 (예상)
단계
- 2 단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Jun Bai
- 전화번호: +86-13186055863
- 이메일: baijun@yahoo.com
연구 연락처 백업
- 이름: Yu Lei
- 전화번호: +86-18682984013
- 이메일: leiyu1981@126.com
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Patients must be NSCLC confirmed by Histological or cytological;
- The NSCLC harbors EGFR-mutation and are previously untreated
- Patient must have measurable lesion and in stage IIIB or IV disease (includes M1a, M1b stages or recurrent disease) (according to the 7th edition of the tumor node metastasis (TNM) classification system).
- Patients be age >18 years and < 75 years.
- Patients must have a Life Expectancy of greater than 12 weeks.
- Patients must have an ECOG performance status 0 to 2.
- Patients must have normal organ and marrow function as defined below, within one week prior to randomization: absolute neutrophil count>1,500/mL platelets>100,000/mL total bilirubin: within normal institutional limits AST/ALT<2.5X institutional upper limit of normal creatinine≤1.5X institutional upper limit of normal urine dipstick for proteinuria of < less than 1+. If urine dipstick is > 1+ then a 24 hour urine for protein must demonstrate <500mg of protein in 24 hours to allow participation in the study.
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- Patients must have an international normalized ratio (INR) < 1.5 and a partial thromboplastin time (PTT) no greater than upper limits of normal within 1 week prior to randomization.
- Patients with a history of hypertension must be well-controlled (<150 systolic/<100 diastolic) on a stable regimen of anti-hypertensive therapy.
- Patients must be able to swallow tablets.
- Patients must have the ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Patients with uncontrolled illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements.
- Patients receiving therapeutic anticoagulation. Prophylactic anticoagulation of venous access devices is allowed provided Section 3.10 is met. Caution should be taken on treating patients with low dose heparin or low molecular weight heparin for DVT prophylaxis during treatment with bevacizumab as there may be an increased risk of bleeding.
- Patients cannot administer aspirin for the risk of bleeding or having stomach ulcers.
- Prior use of chemotherapy.
- Patients receiving immunotherapy, hormonal-therapy and or radiotherapy within 2 weeks prior to entering the study. Note: Those who have not recovered from adverse events due to these agents administered will be considered ineligible.
- Patients receiving any other investigational agents.
- Patients with uncontrolled brain metastasis. Note: Patients with brain metastases must have stable neurologic status following local therapy (surgery or radiation) for at least 2 weeks, and must be without neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
- Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to thalidomide、gefitinib and aspirin or other agents used in the study are excluded.
- Women that are pregnant or breastfeeding Note: Pregnant women are excluded from this study because the agents used in this study may be teratogenic to a fetus. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with thalidomide, breastfeeding women are also excluded from this study.
- HIV-positive Patients that are on combination antiretroviral therapy due to the potential for lethal infections when treated with marrow-suppressive therapy.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: A:gefitinib and thalidomide/aspirin
intervention: drug: gefitinib and thalidomide/aspirin: gefitinib will be administered at 250mg QD continuously; thalidomide will be administered at 100mg QD at night continuously; aspirin will be administered at 100mg QD continuously;
|
|
위약 비교기: B:Placebo
intervention: drug: gefitinib and placebo/aspirin: gefitinib will be administered at 250mg QD continuously; placebo will be given to patients in the same way as the thalidomide; aspirin will be administered at 100mg QD continuously;
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
progression-free survival (PFS)
기간: 1 year
|
one year progression-free survival of the patients
|
1 year
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Objective Response Rate (ORR)
기간: 2 years
|
the Objective Response Rate
|
2 years
|
Overall Survival (OS)
기간: 2 years
|
2 years Overall Survival
|
2 years
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
IL-2 level
기간: 2 years
|
IL-2 level in serum of patients
|
2 years
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Jun Bai, Shaanxi Provincial People's Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- GELI
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
NSCLC에 대한 임상 시험
-
Centre Oscar LambretUniversity Hospital, Lille종료됨
-
Suzhou Zelgen Biopharmaceuticals Co.,Ltd완전한
-
Radboud University Medical CenterPfizer; ImaginAb, Inc.; University Hospital Tuebingen아직 모집하지 않음
위약에 대한 임상 시험
-
AJU Pharm Co., Ltd.OM Pharma SA모병
-
University Hospital, Strasbourg, France모집하지 않고 적극적으로